Salix issued Xifaxan patent

By Lisa Kerner

Erie, Pa., May 18 - Salix Pharmaceuticals, Ltd. said the U.S. Patent and Trademark Office has issued the company a patent entitled "Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations."

The composition of matter patent (U.S. Patent No. 7,045,620) covering several physical states of Xifaxan, is believed to extend the patent coverage of the current form of rifaximin, marketed in the United States under the trade name Xifaxan, until May 22, 2024, according to a company news release.

Alfa Wassermann SpA, the patent owner, has licensed rights to rifaximin in the United States to Salix.

"The issuance of this patent is an important component of our Xifaxan Life Cycle Management program," president and chief executive officer Carolyn Logan stated in the release.

"We continue to move forward with increased confidence in our efforts to discover, develop and commercialize Xifaxan to its fullest potential."

Salix, based in Raleigh, N.C., develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.